Therapeutic agent for chronic arthritides diseases of childhood-related diseases

Patent metadata

Field	Value
Publication number	US-9255145-B2
Application number	US-201113064953-A
Country	US
Kind code	B2
Filing date	Apr 28, 2011
Priority date	Apr 2, 2001
Publication date	Feb 9, 2016
Grant date	Feb 9, 2016

Abstract

A therapeutic agent for chronic arthritides diseases of childhood-related diseases, for example chronic arthritides diseases of childhood, Still's disease and the like, comprising an interleukin-6 (IL-6) antagonist as an active ingredient.

First claim

The invention claimed is:

1. A method for treatment of systemic-onset type juvenile rheumatoid arthritis, comprising administering an antibody against human IL-6 receptor to a human patient who needs said treatment, wherein the antibody against the IL-6 receptor is an antibody which inhibits binding of IL-6 to the IL-6 receptor by binding to the IL-6 receptor.

2. A method according to claim 1 , wherein the systemic-onset type juvenile rheumatoid arthritis is: in the ARA classification, systemic onset; in the EULAR classification, systemic onset; in the ILAR classification, systemic onset; and in the classification by the present inventors, SPRASH syndrome.

3. A method according to claim 1 , wherein the antibody against the IL-6 receptor is a monoclonal antibody.

4. A method according to claim 1 , wherein the antibody against IL-6 receptor is a recombinant antibody.

5. A method according to claim 3 , wherein the monoclonal antibody against human IL-6 receptor is the PM-1 antibody (FERM BP-2998) or a humanized or chimeric version thereof.

6. A method according to claim 1 , wherein the antibody against an IL-6 receptor is a chimeric antibody, a humanized antibody or a human antibody.

7. A method according to claim 6 , wherein the humanized antibody is a variant of PM-1 antibody (FERM BP-2998).

8. A method for treatment of systemic-onset type juvenile rheumatoid arthritis (sJIA) in a human patient comprising administering a therapeutically effective amount of humanized PM-1 antibody to the patient.

Assignees

• Yoshizaki Kazuyuki
• Nishimoto Norihiro
• Iwamoto Masahiro
• Minota Seiji
• Yokota Shumpei
• Miyamae Takako
• Chugai Pharmaceutical Co Ltd

Inventors

• Yoshizaki Kazuyuki
• Nishimoto Norihiro
• Iwamoto Masahiro
• Minota Seiji
• Yokota Shumpei
• Miyamae Takako

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P19/02

  for joint disorders, e.g. arthritis, arthrosis · CPC title

• A61K2039/505

  comprising antibodies · CPC title